Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion (Trials, (2021), 22, 1, (550), 10.1186/s13063-021-05461-9)
Halford S., Wan S., Dragoni I., Silvester J., Nazarov B., Anthony D., Anthony S., Ladds E., Norrie J., Dhaliwal K.
Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au). The original article has been corrected.